<DOC>
	<DOCNO>NCT00081302</DOCNO>
	<brief_summary>RATIONALE : Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Drugs use chemotherapy , paclitaxel carboplatin , work different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving cetuximab together combination chemotherapy radiation therapy may kill tumor cell . PURPOSE : This phase II trial study well give cetuximab together paclitaxel , carboplatin , radiation therapy work treat patient unresectable stage IIIA stage IIIB non-small cell lung cancer .</brief_summary>
	<brief_title>Cetuximab , Paclitaxel , Carboplatin , Radiation Therapy Treating Patients With Unresectable Stage IIIA Stage IIIB Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine feasibility cetuximab administer concurrently paclitaxel , carboplatin , radiotherapy , term safety compliance , patient unresectable stage IIIA IIIB non-small cell lung cancer . Secondary - Determine response rate ( complete partial ) patient treat regimen . - Determine overall survival ( 1- 2-year survival rate median survival ) patient treat regimen . - Determine time disease progression ( 1 2 year ) patient treat regimen . - Correlate epidermal growth factor receptor expression toxicity regimen response , overall survival , progression patient . OUTLINE : This multicenter study . - Cetuximab load dose ( week 1 ) : Patients receive load dose cetuximab IV 2 hour day 1 . - Concurrent cetuximab chemoradiotherapy ( week 2-8 ) : Patients receive cetuximab IV 1 hour , paclitaxel IV 1 hour , carboplatin IV 30 minute day 8 , 15 , 22 , 29 , 36 , 43 , 50 . Patients undergo radiotherapy daily day 8-12 , 15-19 , 22-26 , 29-33 , 36-40 , 43-47 , 50-53 . - Consolidation therapy ( week 9-17 ) : Patients receive cetuximab IV 1 hour day 57 , 64 , 71 , 78 , 85 , 92 , 99 , 106 , 113 . Patients also receive paclitaxel IV 3 hour carboplatin IV 30 minute day 78 99 . Treatment continue absence disease progression unacceptable toxicity . Patients follow 30 day , every 3 month 2 year , every 4 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 84 patient accrue study within 1 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm nonsmall cell lung cancer ( NSCLC ) 1 follow subtypes : Squamous cell carcinoma Adenocarcinoma ( include bronchoalveolar cell ) Large cell anaplastic carcinoma ( include giant clear cell carcinoma ) Poorly differentiated/not otherwise specify NSCLC Stage IIIA ( T12 , N2 , M0 T3 , N12 , M0 ) IIIB ( T4 , N , M0 T , N23 , M0 ) If large mediastinal node &lt; 2.0 cm diameter basis stage III disease , least 1 node must cytologically histologically positive Unresectable disease No totally resect tumor Tumors adjacent vertebral body allow provided gross disease encompass radiation boost field boost volume limit &lt; 50 % ipsilateral lung volume Measurable disease Transudate , cytologically negative , nonbloody pleural effusion allow provided tumor encompass within reasonable field radiotherapy Pleural effusion see chest CT scan allow provide visible chest xray small tap No asymptomatic symptomatic brain metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Zubrod 01 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9 g/dL ( transfusion independent ) Hepatic Bilirubin ≤ 1.5 mg/dL SGOT ( serum glutamic oxaloacetic transaminase ) SGPT ( serum glutamate pyruvate transaminase ) ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 time ULN Renal Creatinine ≤ 2.0 mg/dL Cardiovascular No significant history cardiac disease No uncontrolled hypertension No unstable angina No uncompensated congestive heart failure No myocardial infarction within past year No cardiac ventricular arrhythmia require medication LVEF ( leave ventricular ejection fraction ) normal MUGA ( multigated acquisition ) scan echocardiogram Pulmonary No history interstitial pneumonitis No history severe chronic obstructive pulmonary disease require 3 hospitalization within past year FEV_1 ≥ 1,200 cc No active pulmonary infection unresponsive conventional antibiotic Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 4 week study therapy Glucose ≤ 2 time ULN No 5 % weight loss within past 3 month No know allergy murine protein Cremophor EL No neuropathy grade 2 great No malignancy within past 2 year except adequately treat basal cell squamous cell skin cancer , carcinoma situ cervix , situ cancer PRIOR CONCURRENT THERAPY : Biologic therapy No prior drug target epidermal growth factor receptor pathway No prior chimerized monoclonal antibody therapy No concurrent immunotherapy No concurrent colonystimulating factor ( i.e. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Concurrent epoetin alfa allow Chemotherapy No prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy No concurrent hormonal therapy except hormone nondiseaserelated condition ( e.g. , insulin diabetes ) steroid acute symptom management , adrenal failure , septic shock , antiemetic Radiotherapy No prior thoracic neck radiotherapy No concurrent intensitymodulated radiotherapy Surgery Recovered prior exploratory thoracotomy No prior surgical resection present cancer Other More 30 day since prior participation another clinical trial No concurrent participation another clinical trial No concurrent anticancer therapy No amifostine 3 month study radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>bronchoalveolar cell lung cancer</keyword>
</DOC>